Antibodies Against Alzheimer's Disease - The Douglas Institute is part of an international effort to investigate a new treatment



    MONTREAL, Jan. 13 /CNW Telbec/ - A vaccine-based approach could be an
effective therapy for people with mild or moderate forms of Alzheimer's
disease. The medication used for this therapy will be tested at the Douglas
Mental Health University Institute, participating in an international effort
to find out more about this treatment.
    "Most current therapies for Alzheimer's treat the symptoms associated
with it and not the disease itself. Our goal with this clinical trial is to
explore if this investigational drug can help control the progression of
Alzheimer's," says N. P. Vasavan Nair, MD, director of Human
Psychopharmacology Trials at the Douglas and principal researcher on this
study.
    Alzheimer's disease is a neurodegenerative disorder characterized by
progressive loss of memory and cognitive function. It destroys brain cells,
causing problems with memory, thinking and behaviour severe enough to affect
everyday life. Alzheimer's gets worse over time, and it is fatal. "This new
study will look at how the investigational drug can eliminate the protein
(beta-amyloid) causing the damage," adds Dr. Nair. Dr. Nair is participating
in ICARA (Investigational Clinical Amyloid Research in Alzheimer's) -an
international clinical study to learn if an investigational drug can help
control the progression of Alzheimer's disease. In total, approximately 2,050
patients will be enrolled at research sites in North America.

    Seeking Study Volunteers With Alzheimer's Disease

    Dr Nair points out that it is important for patients and families
affected by Alzheimer's to consider participating in clinical studies.
"Clinical studies that test new treatments are the best chance we have for
fighting this disease." Participants for the ICARA study must be between 50
and 88 years of age, have a diagnosis of mild to moderate Alzheimer's disease
and have a caregiver who is willing to be involved in the study. A medical
team, including a nurse or study coordinator and a physician, will monitor
participants throughout the study.

    To find out more about the study, visit www.douglasrecherche.qc.ca/icara
or contact Dr. Nair's team: Tanya Bossy at 514-761-6131, ext. 4406 or
Jennie-Laure Sully at 514 761-6131, ext. 3458.

    About the Douglas Institute-www.douglas.qc.ca

    The Douglas Mental Health University Institute is a world-class
institute, affiliated with McGill University and World Health Organization,
which treats people suffering from mental illness and offers them hope and
cures. Its teams of specialists and researchers continually advance scientific
knowledge, integrate it into patient care, and share it with the community to
increase awareness and thus eliminate stigma around mental illness.




For further information:

For further information: Marie france Coutu, (514) 761-6131, ext. 2769,
Cell: (514) 835-3236, marie-france.coutu@douglas.mcgill.ca

Organization Profile

Douglas Mental Health University Institute

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890